Aerosol pollution impacts

Aerosol pollution impacts have significant implications for the field of pharmaceutics, particularly in the development and delivery of inhalation therapies. Aerosols are commonly used in drug delivery systems such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), especially for respiratory conditions like asthma and COPD. However, the presence of environmental aerosol pollutants—such as particulate matter (PM2.5 and PM10), soot, and toxic chemicals—can interfere with the efficiency of drug deposition in the lungs. These pollutants may alter the aerodynamic behavior of pharmaceutical aerosols, potentially reducing drug absorption and therapeutic efficacy. Furthermore, chronic exposure to aerosol pollution may induce inflammation or compromise the respiratory tract’s mucosal lining, thereby affecting drug permeability and patient response to treatment.

Beyond drug delivery, aerosol pollution poses challenges in pharmaceutical manufacturing and storage. Airborne contaminants can infiltrate cleanrooms and production environments, threatening the sterility and stability of aerosol-based formulations. This necessitates stricter air quality control and filtration systems within pharmaceutical facilities to prevent product degradation and contamination. Additionally, exposure to polluted air may influence the stability of excipients and active pharmaceutical ingredients (APIs), especially in hygroscopic or oxidation-sensitive formulations. As a result, pharmaceutics must continuously adapt its technologies and regulatory standards to mitigate the impact of aerosol pollution on both therapeutic outcomes and production quality.